Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
12 November 2018 |
Main ID: |
EUCTR2011-005400-15-GR |
Date of registration:
|
09/08/2012 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A clinical study to assess the safety and efficacy of AMG 145 on low density cholesterol in subjects with homozygous familial hypercholesterolemia or PCSK9 mutations
|
Scientific title:
|
A Multicenter, Single Arm, Open-label Study to Assess the Long-term Safety and Efficacy of AMG 145 on LDL-C in Subjects With Homozygous Familial Hypercholesterolemia or PCSK9 Mutations |
Date of first enrolment:
|
05/09/2012 |
Target sample size:
|
75 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005400-15 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: Open: Single blind: Double blind: Parallel group: Cross over: Other: If controlled, specify comparator, Other Medicinial Product: Placebo: Other: Number of treatment arms in the trial: 1
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Canada
|
Czech Republic
|
Greece
|
Italy
|
Netherlands
|
South Africa
|
Spain
|
United Kingdom
|
United States
| | | | | | |
Contacts
|
Name:
|
IHQ Medical Info - Clinical Trials
|
Address:
|
Dammstrasse 23, P.O. Box 1557
(CH-)6300
Zug
Switzerland |
Telephone:
|
N/A |
Email:
|
MedinfoInternational@amgen.com |
Affiliation:
|
Amgen (EUROPE) GmbH |
|
Name:
|
IHQ Medical Info - Clinical Trials
|
Address:
|
Dammstrasse 23, P.O. Box 1557
(CH-)6300
Zug
Switzerland |
Telephone:
|
N/A |
Email:
|
MedinfoInternational@amgen.com |
Affiliation:
|
Amgen (EUROPE) GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Subjects have completed study 20110233 or another qualifying Amgen protocol (all scheduled visits) and are still taking investigational product at the end of the study
Or
If the subjects did not complete study 20110233 or another qualifying Amgen protocol they will be eligible if they:
- Have severe familial hypercholesterolemia due to genetic causes (beyond LDL receptor mutations) which were not studied in 20110233, such as PCSK9 gain of function mutations, as evidenced by genetic or functional evidence.
- Have a diagnosis of homozygous familial hypercholesterolemia and are interested in enrolling after 20110233 has closed. As stated in protocol 20110233, the diagnosis of homozygous familial hypercholesterolemia will be based on genetic confirmation or a clinical diagnosis based on a history of an untreated LDL cholesterol concentration greater than 500
mg/dl (13 mmol/L) together with either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents.
- Are male or female = 12 to = 65 years of age
- Are on a stable on a low-fat diet and taking pre-existing lipid-lowering therapies (such as statins, cholesterol-absorption inhibitors, bile-acid sequestrants or nicotinic acid, or combinations thereof) for at least 4 weeks, with fasting central lab LDL cholesterol concentration >130 (3.4 mmol/L)
- Fasting triglycerides = 400 mg/dL (4.5 mmol/L) by central laboratory at screening
- Bodyweight of 40 kg or greater at screening Are the trial subjects under 18? yes Number of subjects for this age range: 15 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10
Exclusion criteria: All subjects will be ineligible for the study if they fulfill any of the following criteria:
- Female subject is not willing to use at least one highly effective method of birth control during treatment and for an additional 15 weeks after the end of treatment unless subject is sterilized or postmenopausal;
• Menopause is defined as 12 months of spontaneous and continuous amenorrhea in a female = 55 years old or 12 months of spontaneous and continuous amenorrhea with a follicle-stimulating hormone level >40 IU/L (or according to the definition of "postmenopausal range" for the laboratory involved) in a female < 55 years old unless the subject has undergone bilateral oophorectomy”
• Highly effective methods of birth control include abstinence, birth control pills, shots, implants, or patches, intrauterine devices (IUDs), sexual activity with a male partner who has had a vasectomy, condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicide.
- Subject is pregnant or breast feeding, or might become pregnant during treatment and/or within 15 weeks after the end of treatment
- Unreliability as a study participant based on the investigator's (or designee’s) knowledge of the subject (eg, inability or unwillingness to adhere to the protocol)
- Experienced a treatment related serious adverse event in the parent study
- Disorder that would interfere with understanding and giving informed consent or compliance with protocol requirements
Have an unstable medical condition, in the judgment of the investigator.
- Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)
If the subjects did not complete study 20110233 or another qualifying Amgen protocol they will be ineligible for this study if they fulfill any of the following criteria:
- Use of Mipomersen within 5 months of screening
- NYHA III or IV heart failure, or last known left ventricular ejection fraction < 30%
- Uncontrolled serious cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization
- Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
- Planned cardiac surgery or revascularization within 20 weeks of screening
- Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) > 180 mmHg or diastolic BP (DBP) > 110 mmHg, confirmed with repeat measurement
- Subject requires uptitration of their current statin dose within 4 weeks of screening (these subjects can be uptitrated and rescreened one month later)
- Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 at screening
- Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN as determined by central laboratory analysis at screening
- Unexplained CK > 5 times the ULN at screening, confirmed by a repeat measurement at least 1 week apart
- Known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction in the judgment of the investigator
- Diagnosis of d
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|
Homozygous Familial Hypercholesterolemia MedDRA version: 14.1
Level: LLT
Classification code 10057100
Term: Homozygous familial hypercholesterolaemia
System Organ Class: 10010331 - Congenital, familial and genetic disorders
|
Intervention(s)
|
Product Name: AMG 145 Product Code: AMG 145 Pharmaceutical Form: Solution for injection Current Sponsor code: AMG 145 Other descriptive name: AMG 145 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use
|
Primary Outcome(s)
|
Main Objective: To characterize the safety and tolerability of long-term administration of AMG 145 among patients with severe familial hypercholesterolemia
|
Primary end point(s): Subject incidence of treatment emergent adverse events.
|
Secondary Objective: To characterize the durable efficacy of long-term administration of AMG 145 as assessed by low density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), total cholesterol/HDL-C ratio, and ApoB/Apolipoprotein A-1 (ApoA1) ratio in subjects with severe familial hypercholesterolemia
|
Timepoint(s) of evaluation of this end point: From baseline to week 26 Q4W; quaterly after week 26 until EoS
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: • Percent change in LDL-C from Day 1 OL at each 3 month visit
• Percent change in non-HDL-C from Day 1 OL at each 3 month visit
• Percent change in ApoB from Day 1 OL at each 3 month visit
• Percent change in total cholesterol/HDL-C ratio from Day 1 OL at each 3 month visit
• Percent change in ApoB/ApoA1 ratio from Day 1 OL at each 3 month visit
|
Secondary end point(s): • Percent change in LDL-C from Day 1 OL at each 3 month visit
• Percent change in non-HDL-C from Day 1 OL at each 3 month visit
• Percent change in ApoB from Day 1 OL at each 3 month visit
• Percent change in total cholesterol/HDL-C ratio from Day 1 OL at each 3 month visit
• Percent change in ApoB/ApoA1 ratio from Day 1 OL at each 3 month visit
|
Secondary ID(s)
|
20110271
|
2011-005400-15-BE
|
Source(s) of Monetary Support
|
Amgen Inc
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|